The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Table of contents


Chemical Compound Review

MLS000028585     aluminum; (2R,3R,4S,5R,6S)-3,4,5...

Synonyms: SMR000058992
This record was replaced with 5312151.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of (2R,3R,4S,5R,6S)-3,4,5-trisulfoxy-2-(sulfoxymethyl)-6-[(2R,3S,4S,5R)-3,4,5-trisulfoxy-2-(sulfoxymethyl)tetrahydrofuran-2-yl]oxy-tetrahydropyran


Psychiatry related information on (2R,3R,4S,5R,6S)-3,4,5-trisulfoxy-2-(sulfoxymethyl)-6-[(2R,3S,4S,5R)-3,4,5-trisulfoxy-2-(sulfoxymethyl)tetrahydrofuran-2-yl]oxy-tetrahydropyran

  • These results suggest that the 2 g b.i.d. dose of sucralfate in granule form is at least as effective as the conventional dose of 1 g q.i.d. in the treatment of active gastric ulcers and could lead to better patient compliance [6].
  • At the base-case assumptions of 6% risk of developing stress-related hemorrhage and 50% risk-reduction due to prophylaxis, the cost of sucralfate was $1,144 per bleeding episode averted [7].
  • After 2 years of follow-up, sucralfate was found to be superior to both placebo and antacid (P < 0.001) with regard to duration of pain, reduction of the healing period, response time to first treatment and duration of remission [8].
  • Endoscopy showed symptomatic improvement in 67% of the patients treated with sucralfate and in 74% of the combination therapy group [9].
  • Sucralfate dose-dependently decreased the clinical signs of enterocolitis (e.g., lethargy, diarrhea) as well as the number and area of ileal and colonic erosions and ulcers [10].

High impact information on (2R,3R,4S,5R,6S)-3,4,5-trisulfoxy-2-(sulfoxymethyl)-6-[(2R,3S,4S,5R)-3,4,5-trisulfoxy-2-(sulfoxymethyl)tetrahydrofuran-2-yl]oxy-tetrahydropyran


Chemical compound and disease context of (2R,3R,4S,5R,6S)-3,4,5-trisulfoxy-2-(sulfoxymethyl)-6-[(2R,3S,4S,5R)-3,4,5-trisulfoxy-2-(sulfoxymethyl)tetrahydrofuran-2-yl]oxy-tetrahydropyran


Biological context of (2R,3R,4S,5R,6S)-3,4,5-trisulfoxy-2-(sulfoxymethyl)-6-[(2R,3S,4S,5R)-3,4,5-trisulfoxy-2-(sulfoxymethyl)tetrahydrofuran-2-yl]oxy-tetrahydropyran


Anatomical context of (2R,3R,4S,5R,6S)-3,4,5-trisulfoxy-2-(sulfoxymethyl)-6-[(2R,3S,4S,5R)-3,4,5-trisulfoxy-2-(sulfoxymethyl)tetrahydrofuran-2-yl]oxy-tetrahydropyran


Associations of (2R,3R,4S,5R,6S)-3,4,5-trisulfoxy-2-(sulfoxymethyl)-6-[(2R,3S,4S,5R)-3,4,5-trisulfoxy-2-(sulfoxymethyl)tetrahydrofuran-2-yl]oxy-tetrahydropyran with other chemical compounds

  • Several in vitro tests suggested that the clear sucrose sulfate solution, like the sucralfate gel, probably acts through a topical protectant effect, rather than through pepsin inactivation [21].
  • These results indicate that sucralfate can protect against acid injury in esophagus and that this protection is mediated by (a) intraluminal pH buffering through its content of aluminum hydroxide and (b) enhancing mucosal defense against H+ entry and injury through its content of SOS [20].
  • Animals were exposed for 1 h to either acid alone (HCl at pH 2), acid plus pepsin (0.8 mg/ml), or acid plus taurocholic acid (5 mM), as well as to the same injurious agents with the addition of 1 g of sucralfate [21].
  • Nosocomial pneumonia was diagnosed in 6%, 12%, and 13% of controls, sucralfate recipients, and cimetidine recipients, respectively (sucralfate: relative risk, 2.0 [CI, 0.79 to 5.01], P = 0.14; cimetidine: relative risk, 2.2 [CI, 0.88 to 5.33], P = 0.09) [22].
  • Ranitidine alone or combined with sucralfate did not prevent ethanol-induced histologic or functional changes in the mucosa [23].

Gene context of (2R,3R,4S,5R,6S)-3,4,5-trisulfoxy-2-(sulfoxymethyl)-6-[(2R,3S,4S,5R)-3,4,5-trisulfoxy-2-(sulfoxymethyl)tetrahydrofuran-2-yl]oxy-tetrahydropyran


Analytical, diagnostic and therapeutic context of (2R,3R,4S,5R,6S)-3,4,5-trisulfoxy-2-(sulfoxymethyl)-6-[(2R,3S,4S,5R)-3,4,5-trisulfoxy-2-(sulfoxymethyl)tetrahydrofuran-2-yl]oxy-tetrahydropyran

  • GRP-stimulated plasma gastrin concentrations, GRP-stimulated acid output, and basal acid output all decreased by approximately 50% during sucralfate therapy and returned to pretreatment levels after treatment was discontinued [3].
  • Healing of the ulcer was documented 8 wk after vagotomy, antrectomy, gastrojejunostomy, and a course of sucralfate therapy [29].
  • Eight chair-adapted rhesus monkeys received a subcutaneous injection of either 150 mg/kg of aspirin or vehicle in combination with either a therapeutic oral dose of sucralfate (50 mg/kg X day) or water [5].
  • Protective effect of sucralfate against alcohol-induced gastric mucosal injury in the rat. Macroscopic, histologic, ultrastructural, and functional time sequence analysis [30].
  • INTERVENTIONS: Patients who were expected to receive at least 3 months of NSAID therapy and who did not have a gastric ulcer at the time of the initial screening endoscopy were randomized to receive misoprostol, 200 micrograms four times a day, or sucralfate, 1 g four times a day [14].


  1. Oral sucralfate suspension for mucositis. Solomon, M.A. N. Engl. J. Med. (1986) [Pubmed]
  2. Sucralfate bezoar. Algozzine, G.J., Hill, G., Scoggins, W.G., Marr, M.A. N. Engl. J. Med. (1983) [Pubmed]
  3. Sucralfate suppresses Helicobacter pylori infection and reduces gastric acid secretion by 50% in patients with duodenal ulcer. Banerjee, S., El-Omar, E., Mowat, A., Ardill, J.E., Park, R.H., Watson, W., Beattie, A.D., McColl, K.E. Gastroenterology (1996) [Pubmed]
  4. Nonsteroidal antiinflammatory drug-induced ulcers: management by traditional therapies. McCarthy, D.M. Gastroenterology (1989) [Pubmed]
  5. Gastric protection by sucralfate. Role of mucus and prostaglandins. Shea-Donohue, T., Steel, L., Montcalm, E., Dubois, A. Gastroenterology (1986) [Pubmed]
  6. Clinical efficacy of sucralfate in the treatment of gastric ulcer. Asaka, M., Takeda, H., Saito, M., Murashima, Y., Miyazaki, T. Am. J. Med. (1991) [Pubmed]
  7. Prophylaxis for stress-related gastrointestinal hemorrhage: a cost effectiveness analysis. Ben-Menachem, T., McCarthy, B.D., Fogel, R., Schiffman, R.M., Patel, R.V., Zarowitz, B.J., Nerenz, D.R., Bresalier, R.S. Crit. Care Med. (1996) [Pubmed]
  8. Sucralfate suspension as a treatment of recurrent aphthous stomatitis. Rattan, J., Schneider, M., Arber, N., Gorsky, M., Dayan, D. J. Intern. Med. (1994) [Pubmed]
  9. Combination therapy of sucralfate and ranitidine, compared with sucralfate monotherapy, in patients with peptic reflux esophagitis. Vermeijden, J.R., Tytgat, G.N., Schotborgh, R.H., Dekker, W., vd Boomgaard, D.M., van Olffen, G.H., Schrijver, M., Vosmaer, G.D., Dekkers, C.P. Scand. J. Gastroenterol. (1992) [Pubmed]
  10. Radiation-induced enterocolitis: basic and applied science. Szabo, S., Sandor, Z., Vincze, A., Gombos, Z., Mohiuddin, A., Viravathana, T. The European journal of surgery. Supplement. : = Acta chirurgica. Supplement. (1998) [Pubmed]
  11. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Cook, D., Guyatt, G., Marshall, J., Leasa, D., Fuller, H., Hall, R., Peters, S., Rutledge, F., Griffith, L., McLellan, A., Wood, G., Kirby, A. N. Engl. J. Med. (1998) [Pubmed]
  12. Sucralfate overcomes adverse effect of cigarette smoking on duodenal ulcer healing and prolongs subsequent remission. Lam, S.K., Hui, W.M., Lau, W.Y., Branicki, F.J., Lai, C.L., Lok, A.S., Ng, M.M., Fok, P.J., Poon, G.P., Choi, T.K. Gastroenterology (1987) [Pubmed]
  13. Prevention of duodenal ulcer recurrence. Strum, W.B. Ann. Intern. Med. (1986) [Pubmed]
  14. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Agrawal, N.M., Roth, S., Graham, D.Y., White, R.H., Germain, B., Brown, J.A., Stromatt, S.C. Ann. Intern. Med. (1991) [Pubmed]
  15. Effects of sucralfate on acute and late bowel discomfort following radiotherapy of pelvic cancer. Henriksson, R., Franzén, L., Littbrand, B. J. Clin. Oncol. (1992) [Pubmed]
  16. Effect of omeprazole and sucralfate on prepyloric gastric ulcer. A double blind comparative trial and one year follow up. Sørensen, H.T., Rasmussen, H.H., Balslev, I., Boesby, S., Boné, J., Kruse, A., Rasmussen, S.N. Gut (1994) [Pubmed]
  17. Aspirin-induced changes in gastric function: role of endogenous prostaglandins and mucosal damage. Shea-Donohue, T., Steel, L., Montcalm-Mazzilli, E., Dubois, A. Gastroenterology (1990) [Pubmed]
  18. Does sucralfate affect the normal gastric mucosa? Histologic, ultrastructural, and functional assessment in the rat. Tarnawski, A., Hollander, D., Krause, W.J., Zipser, R.D., Stachura, J., Gergely, H. Gastroenterology (1986) [Pubmed]
  19. Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. Caillé, G., du Souich, P., Besner, J.G., Gervais, P., Vézina, M. Am. J. Med. (1989) [Pubmed]
  20. Mucosal protection by sucralfate and its components in acid-exposed rabbit esophagus. Orlando, R.C., Turjman, N.A., Tobey, N.A., Schreiner, V.J., Powell, D.W. Gastroenterology (1987) [Pubmed]
  21. Sucralfate prevents experimental peptic esophagitis in rabbits. Schweitzer, E.J., Bass, B.L., Johnson, L.F., Harmon, J.W. Gastroenterology (1985) [Pubmed]
  22. Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. A randomized, controlled, single-blind study. Ben-Menachem, T., Fogel, R., Patel, R.V., Touchette, M., Zarowitz, B.J., Hadzijahic, N., Divine, G., Verter, J., Bresalier, R.S. Ann. Intern. Med. (1994) [Pubmed]
  23. Comparison of sucralfate and ranitidine in gastroprotection against alcohol in humans. Konturek, S.J., Mach, T., Konturek, J.W., Bogdal, J., Stachura, J. Am. J. Med. (1989) [Pubmed]
  24. Sucrose octasulfate stimulates gastric somatostatin release. Lucey, M.R., Park, J., DelValle, J., Wang, L.D., Yamada, T. Am. J. Med. (1991) [Pubmed]
  25. Sucralfate: the Bangkok review. Korman, M.G., Bolin, T.D., Szabo, S., Hunt, R.H., Marks, I.N., Glise, H. J. Gastroenterol. Hepatol. (1994) [Pubmed]
  26. Role of interleukin-4 in down-regulation of endothelin-1 during gastric ulcer healing: effect of sucralfate. Slomiany, B.L., Piotrowski, J., Slomiany, A. J. Physiol. Pharmacol. (2000) [Pubmed]
  27. Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-alpha, bFGF, and EGF receptor expression in humans. Zhang, T., O'Keefe, S.J., Winter, T., Marks, I.N., Ogden, J. Dig. Dis. Sci. (1998) [Pubmed]
  28. Fibroblast growth factor in gastroprotection and ulcer healing: interaction with sucralfate. Konturek, S.J., Brzozowski, T., Majka, J., Szlachcic, A., Bielanski, W., Stachura, J., Otto, W. Gut (1993) [Pubmed]
  29. Postbulbar duodenal ulcer in a patient with pentagastrin-fast achlorhydria. Goldschmiedt, M., Peterson, W.L., Vuitch, F., Feldman, M. Gastroenterology (1989) [Pubmed]
  30. Protective effect of sucralfate against alcohol-induced gastric mucosal injury in the rat. Macroscopic, histologic, ultrastructural, and functional time sequence analysis. Hollander, D., Tarnawski, A., Krause, W.J., Gergely, H. Gastroenterology (1985) [Pubmed]
WikiGenes - Universities